Adapthealth Corp. · NASDAQ:AHCO
Adapthealth — Q3 2024 Earnings Presentation
12 slides from Adapthealth's earnings presentation, November 2024
Slide 1: Financial Supplement Q3 2024
Financial Supplement Q3 2024
Slide 2: Disclaimer
Disclaimer This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management's current views concerning future business, events, trends, contingencies, financial performance, or financial con dition,
Slide 3: Summary Financial Results
Summary Financial Results (in thousands, except percentages) Three Months Ended September 30, June 30, March 31, December 31, September 30, 2024 2024 2024 2023 2023 Sales revenue $ 510,693 $ 516,405 $ 506,140 $ 585,289 $ 532,125 Rental revenue 262,315 258,326 254,338 272,945 271,906 Capitated revenu
Slide 4: Q3 2024 Business Mix Summary
Q3 2024 Business Mix Summary Other 9.2% Patient HME Pay 6.6% 13.3% Rental 32.5% Sleep 40.5% Respiratory Government 20.4% 25.9% Insurance Sale 60.8% Capitated 63.4% 4.1% Supplies to the Home 5.8% Diabetes 17.5% Sale Type Product Payor / Investor Supplement / Q3 2024 4
Slide 5: Revenue by Product (1 of 2)
Revenue by Product (1 of 2) (in thousands) Three Months Ended September 30, June 30, March 31, December 31, September 30, 2024 2024 2024 2023 2023 Net sales revenue Sleep $ 237,537 $ 233,361 $ 225,526 $ 240,808 $ 227,005 Diabetes 137,099 147,261 146,979 182,538 157,328 Supples to the home 43,534 44,
Slide 6: Revenue by Product (2 of 2)
Revenue by Product (2 of 2) (in thousands) Three Months Ended September 30, June 30, March 31, December 31, September 30, 2024 2024 2024 2023 2023 Net revenue from capitated revenue arrangements Sleep $ 7,380 $ 6,976 $ 7,052 $ - $ - Diabetes 1,535 1,546 1,598 - - Supples to the home 3,246 3,080 3,21
Slide 7: Net Revenue Growth
Net Revenue Growth In millions Reported Net Revenue Growth Non-Acquired Net Revenue Growth (1) +0.2% +0.2% 9.7% ~$804 ~$806 ~$804 ~$806 6.0% 6.2% 1.5% 0.2% Q3’23 Q3’24 Q3’23 Q3’24 Q3’23 Q4’23 Q1’24 Q2’24 Q3’24 Reported Reported Non-Acquired Non-Acquired (1) Non-Acquired net revenue compares the reve
Slide 8: Appendix
Appendix
Slide 9: Non-GAAP Reconciliation
Non-GAAP Reconciliation Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenue Revenue Revenue Revenue (in thousands, except percentages) Dollars Percentage Dollars Percentage Dollars Percentage Dollars Percentage Net income (loss) attributable to AdaptHealth Co
Slide 10: Free Cash Flow
Free Cash Flow (in thousands) Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2024 2023 2024 2023 Net cash provided by operating activities $ 144,405 $ 98,833 $ 391,424 $ 325,400 Purchases of equipment and other fixed assets (59,556) (77,086) (228,719) (2
Slide 11: Share Count Information
Share Count Information Total Common and Preferred Stock if (in thousands) Common Stock Preferred Stock (1) Converted Number of shares outstanding, June 30, 2024 133,377 124 145,783 Equity-based compensation activity 79 - 79 Exercise of stock options 44 - 44 Employee stock purchase plan activity 39
Slide 12: Earnings Per Share (EPS)
Earnings Per Share (EPS) Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except per share data) 2024 2023 2024 2023 Numerator Net income (loss) attributable to AdaptHealth Corp. $ 22,859 $ (454,076) $ 40,160 $ (424,392) Less: Earnings allocated to participating securi